Get the Stockscreener App
2.94
2.44%
0.07
After Hours:
2.94
Erasca Inc stock is traded at $2.94, with a volume of 1.11M.
It is up +2.44% in the last 24 hours and up +15.75% over the past month.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
See More
Previous Close:
$2.87
Open:
$2.88
24h Volume:
1.11M
Relative Volume:
0.59
Market Cap:
$830.56M
Revenue:
-
Net Income/Loss:
$-125.04M
P/E Ratio:
-1.6517
EPS:
-1.78
Net Cash Flow:
$-122.99M
1W Performance:
+5.00%
1M Performance:
+15.75%
6M Performance:
+37.38%
1Y Performance:
+21.49%
1-Day Range:
$2.785
$2.95
1-Week Range:
$2.59
$2.95
52-Week Range:
$1.51
$3.45
Erasca Inc Stock (ERAS) Company Profile
Name
Erasca Inc
Sector
Industry
Phone
(858) 465-6511
Address
10835 ROAD TO THE CURE, SUITE 140, SAN DIEGO
Erasca Inc Stock (ERAS) Latest News
Erasca to Present at Upcoming Investor Conferences - ForexTV.com
Erasca Insiders Added US$1.95m Of Stock To Their Holdings - Yahoo Finance
Erasca (NASDAQ:ERAS) Shares Up 3.8%Should You Buy? - MarketBeat
The Goldman Sachs Group Raises Erasca (NASDAQ:ERAS) Price Target to $3.50 - Defense World
Erasca (NASDAQ:ERAS) Trading Down 3.4%What's Next? - MarketBeat
Erasca Inc (NASDAQ: ERAS) Stock: Bulls Should Watch This - Stocks Register
Erasca stock gains momentum as Goldman sees potential in melanoma treatment - Investing.com Canada
HC Wainwright Reaffirms Buy Rating for Erasca (NASDAQ:ERAS) - MarketBeat
Erasca reports progress in melanoma treatment trials - Investing.com India
Erasca reports progress in melanoma treatment trials By Investing.com - Investing.com UK
Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise - The Manila Times
Erasca, Inc. (NASDAQ:ERAS) Holdings Lowered by Exchange Traded Concepts LLC - Defense World
The Manufacturers Life Insurance Company Increases Stock Holdings in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Stock Performance Spotlight: Erasca Inc (ERAS) Ends the Day at 2.81, Up by 2.18 - The Dwinnex
A look into Erasca Inc (ERAS)’s deeper side - SETE News
We Think Erasca (NASDAQ:ERAS) Can Afford To Drive Business Growth - Simply Wall St
Do investors need to be concerned about Erasca Inc (ERAS)? - US Post News
Erasca Inc [ERAS] Investment Guide: What You Need to Know - Knox Daily
Renaissance Technologies LLC Invests $195,000 in SkyWater Technology, Inc. (NASDAQ:SKYT) - Defense World
Erasca Inc [ERAS] Shares Rise 3.17 % on Wednesday - Knox Daily
A company insider recently bought 10,000 shares of Lumen Technologies Inc [LUMN]. Should You Buy? - Knox Daily
Insider Selling: Caisley Charles A., Evergy Inc [EVRG] SVP – PA & CHIEF CO divested 9,236 shares - Knox Daily
Chairman, President and CEO Simonelli Lorenzo sold 114,286 shares of Baker Hughes Co [BKR] - Knox Daily
Unitedhealth Group Inc [UNH] stock for 1,624,734 USD was sold by ROOS THOMAS E - Knox Daily
Ocean Power Technologies [OPTT] Stock bought by Insider N/A for $N/A - Knox Daily
Myc Proto Oncogene Protein Clinical Trials 2024: FDA Approvals, Medication, Therapies, MOA, ROA, and Companies by DelveInsight | Biogenera SpA, Ceptur Therapeutics Inc, Cothera Bioscience, more - The Globe and Mail
Russell 1000 Value (TXM25) Quote - The Globe and Mail
A year in review: Erasca Inc (ERAS)’s performance in the last year - US Post News
Ratios Revealed: Decoding Erasca Inc (ERAS)’s Financial Health - The Dwinnex
American Century Companies Inc. Raises Stake in Seritage Growth Properties (NYSE:SRG) - Defense World
Chevron Co. (NYSE:CVX) Shares Acquired by Deane Retirement Strategies Inc. - Defense World
ERAS Stock Sees Decline of Approximately -8.03% in Last Five Days - Knox Daily
Insider Selling: Zoon Kathryn C, Emergent Biosolutions Inc [EBS] Director divested 10,000 shares - Knox Daily
Erasca Inc [ERAS] Is Currently -2.70 below its 200 Period Moving Avg: What Does This Mean? - The DBT News
Erasca Inc: Weathering Stock Market Storms with 686.48M Market Cap - The InvestChronicle
Euronet Worldwide, Inc. (NASDAQ:EEFT) Short Interest Up 8.5% in September - Defense World
How should investors view Erasca Inc (ERAS)? - US Post News
Gold/Mexican Peso (XAUMXN) QuotePress Release - The Globe and Mail
Erasca: New Focus After Restructuring, But Need More Differentiation (NASDAQ:ERAS) - Seeking Alpha
Investing in Erasca Inc (ERAS) Is Getting More Attractive - Knox Daily
It makes sense and dollars to buy Erasca Inc (ERAS) stock - SETE News
Marshall Wace LLP Makes New $8.67 Million Investment in Erasca, Inc. (NASDAQ:ERAS) - MarketBeat
Frazier Life Sciences Management L.P. Makes New Investment in Erasca, Inc. (NASDAQ:ERAS) - MarketBeat
Permian Resources Co. (NYSE:PR) Shares Acquired by Xponance Inc. - Defense World
Asp Isotopes Inc (ASPI-Q) QuotePress Release - The Globe and Mail
You might want to take a look at Erasca Inc (ERAS) now - SETE News
Erasca Inc [ERAS] Records 200-Day SMA of $2.30 - Knox Daily
Bank of New York Mellon Corp Sells 2,802 Shares of VanEck Junior Gold Miners ETF (NYSEARCA:GDXJ) - Defense World
Examining Erasca Inc (ERAS) stock is warranted - US Post News
Affinity Asset Advisors LLC Invests $5.90 Million in Erasca, Inc. (NASDAQ:ERAS) - Defense World
Affinity Asset Advisors LLC Makes New $5.90 Million Investment in Erasca, Inc. (NASDAQ:ERAS) - MarketBeat
Erasca Inc Stock (ERAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):